Objective: Validate the ER-Golgi Secretory Pathway Dysfunction Hypothesis in Parkinson's Disease by testing whether:
- ER-Golgi dysfunction precedes alpha-synuclein aggregation in dopaminergic neurons
- Genetic risk factors (GBA, VPS35, ATP13A9) cause ER-Golgi impairment
- ER-Golgi modulators can prevent or reverse dopaminergic neurodegeneration
Study Design: Multi-phase, multi-arm translational study
Duration: 36 months (12 months per phase)
Characterize ER-Golgi function in dopaminergic neurons derived from PD patients with various genetic backgrounds.
Patient Cohorts:
- Group 1: GBA mutation carriers (n=5)
- Group 2: LRRK2 G2019S carriers (n=5)
- Group 3: VPS35 D620N carriers (n=3)
- Group 4: Sporadic PD (n=5)
- Group 5: Healthy controls (n=5)
Primary Endpoints:
| Endpoint |
Method |
Timepoint |
| ER stress markers |
Western blot: p-PERK, p-eIF2α, CHOP, BiP |
Day 0, 30, 60 |
| Golgi integrity |
GM130 immunostaining + confocal microscopy |
Day 0, 30, 60 |
| XBP1 splicing |
qRT-PCR |
Day 0, 30, 60 |
| Alpha-synuclein aggregation |
pSer129-αSyn IHC |
Day 0, 30, 60 |
| Viability |
ATP assay + caspase 3/7 |
Day 0, 30, 60 |
Secondary Endpoints:
- Mitochondrial function: Seahorse XF analysis
- Autophagy flux: LC3 II turnover
- Calcium homeostasis: Fluo-4 AM imaging
- Synaptic function: Synaptophysin/VGLUT2 puncta analysis
Using ANOVA with 5 groups, α=0.05, power=0.80, effect size=0.5, requires n=3 minimum per group. Using n=5 for robustness.
Determine temporal relationship between ER-Golgi dysfunction and alpha-synuclein aggregation following toxin exposure.
Treatment Groups:
- Vehicle control
- MPTP (1μM, 24h)
- 6-OHDA (100μM, 24h)
- Rotenone (10nM, 72h)
- Paraquat (10μM, 72h)
Cell Type: iPSC-derived dopaminergic neurons (n=3 lines per group)
Timepoints: 2h, 6h, 12h, 24h, 48h, 72h post-treatment
Readouts:
-
Early markers (<6h):
- ER calcium depletion (Fluo-5F AM)
- p-PERK activation (Western blot)
- Golgi dispersion (GM130 staining)
-
Intermediate markers (6-24h):
- XBP1 splicing
- CHOP expression
- p-eIF2α
-
Late markers (24-72h):
- Alpha-synuclein pSer129
- Mitochondrial complex I activity
- Cell viability
Mixed-effects model with treatment × time interaction. Post-hoc Bonferroni correction.
Test whether ER-Golgi modulators protect dopaminergic neurons from toxin-induced degeneration.
Intervention Arms:
| Compound |
Dose |
Mechanism |
Source |
| TUDCA |
200μM |
Chemical chaperone |
Sigma-Aldrich |
| Guanabenz |
10μM |
eIF2α phosphatase inhibitor |
MedChemExpress |
| Salubrinal |
10μM |
eIF2α phosphatase inhibitor |
Selleck Chemicals |
| ISRIB |
5μM |
ATF4 pathway modulator |
Tocris |
| Vehicle |
— |
— |
— |
Toxicity Challenge: MPTP 1μM for 24h (pre-treatment with compounds 1h prior)
Readouts: Cell viability, ER stress markers, Golgi integrity, alpha-synuclein aggregation
Analysis: IC50 determination, synergy assessment (Comburent analysis)
Validate ER-Golgi dysfunction in established mouse models of PD.
- MPTP mouse model (C57BL/6, 8 weeks, male)
- α-Synuclein transgenic (SNCA A53T, Jackson Labs)
- GBA knockout (conditional in neurons)
- VPS35 D620N knock-in
MPTP Model:
- Acute: MPTP 30mg/kg × 5 days, sacrifice day 1, 3, 7, 14
- Chronic: MPTP 20mg/kg × 4 weeks, sacrifice week 1, 4, 8, 12
- Controls: Saline-treated age-matched
Readouts:
- Behavioral: Rotarod, cylinder, gait analysis (pre and post)
- Histological: TH+ neuron count, pSer129-αSyn, IBA1 (microglia), GFAP (astrocytes)
- Molecular: ER stress PCR array, Golgi integrity, mitochondrial complex I
- Biochemical: Striatal dopamine, CSF biomarkers
Sample Size: n=12 per group (power 0.80, effect size 0.8)
Test whether ER-Golgi modulators rescue dopaminergic neurons in vivo.
Treatment Groups (n=12 per group):
- Vehicle (saline, i.p.)
- MPTP + TUDCA (250mg/kg, i.p., daily)
- MPTP + Guanabenz (2mg/kg, i.p., daily)
- MPTP + Salubrinal (1mg/kg, i.p., daily)
- Positive control: MPTP + CoQ10 (100mg/kg, i.p., daily)
Treatment Protocol:
- Pre-treatment: 7 days
- Co-treatment with MPTP: 14 days
- Post-treatment observation: 28 days
Endpoints:
- Primary: TH+ neuron survival in substantia nigra pars compacta
- Secondary: Rotarod performance, striatal dopamine levels
- Exploratory: ER stress markers (qPCR), Golgi morphology (EM)
Identify and validate ER-Golgi pathway biomarkers in PD patients.
Prospective cohort study
Cohorts:
- Early PD (n=50, H&Y 1-2)
- Advanced PD (n=50, H&Y 3-4)
- Prodromal RBD (n=30)
- Healthy controls (n=30)
Biomarker Candidates:
| Biomarker |
Source |
Method |
Pathway |
| BiP/GRP78 |
CSF |
ELISA |
ER chaperone |
| XBP1s mRNA |
PBMCs |
qRT-PCR |
UPR activation |
| p-PERK |
Blood cells |
Western blot |
UPR activation |
| GM130 |
Exosomes |
Western blot |
Golgi integrity |
| TUDCA |
Urine |
LC-MS |
ER stress (metabolite) |
Correlation Analysis:
- UPDRS motor score
- Dopamine transporter imaging (DAT-SPECT)
- CSF alpha-synuclein
- Disease duration
Assess safety and preliminary efficacy of TUDCA in early PD patients.
Randomized, double-blind, placebo-controlled
Population: Early PD (H&Y 1-2, n=60)
Arms (n=20 each):
- TUDCA 500mg BID oral
- TUDCA 1000mg BID oral
- Placebo
Duration: 52 weeks
Endpoints:
- Primary: Safety (adverse events)
- Secondary: Change in UPDRS Part III, MoCA, CSF biomarkers
- Exploratory: ER stress markers in blood, DAT-SPECT change
Mixed-effects models for repeated measures, with treatment as fixed effect, subject as random effect, baseline as covariate.
Bonferroni for primary endpoints, FDR for exploratory endpoints.
- In vitro: n=5 per group, power >0.80 for effect size 1.0
- In vivo: n=12 per group, power >0.80 for effect size 0.8
- Clinical: n=20 per group, power >0.80 for effect size 0.6
- ≥70% of patient-derived neurons show elevated ER stress markers
- Time-course demonstrates ER-Golgi dysfunction precedes α-syn aggregation
- ≥1 compound shows ≥50% neuroprotection in vitro
- Mouse models confirm ER-Golgi dysfunction in vivo
- ≥1 compound shows ≥30% neuron rescue vs. MPTP alone
- Behavioral improvements correlate with molecular markers
- Biomarker panel shows significant difference between PD and controls
- TUDCA shows acceptable safety profile
- Trend toward clinical benefit (UPDRS improvement ≥3 points)
- Electronic data capture (REDCap)
- Centralized biobank (CSF, blood, tissue)
- Blind coding for all experimental groups
- Independent statistical review
- IRB approval for all human studies
- IACUC approval for animal studies
- Informed consent for patient cohorts
- Data safety monitoring board for clinical trial